521 related articles for article (PubMed ID: 24445767)
21. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
[TBL] [Abstract][Full Text] [Related]
22. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
23. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
Ohgaki H; Kleihues P
J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
[TBL] [Abstract][Full Text] [Related]
24. Glioblastoma: pathology, molecular mechanisms and markers.
Aldape K; Zadeh G; Mansouri S; Reifenberger G; von Deimling A
Acta Neuropathol; 2015 Jun; 129(6):829-48. PubMed ID: 25943888
[TBL] [Abstract][Full Text] [Related]
25. Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Fujio S; Kirishima M; Takigawa K; Hata N; Toh K; Yamamoto J; Hanaya R; Tanimoto A; Yoshimoto K
Neurol Med Chir (Tokyo); 2022 Sep; 62(9):391-399. PubMed ID: 36031351
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
[TBL] [Abstract][Full Text] [Related]
27. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma.
Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ
Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900
[TBL] [Abstract][Full Text] [Related]
28. Molecular pathogenesis of IDH mutations in gliomas.
Ichimura K
Brain Tumor Pathol; 2012 Jul; 29(3):131-9. PubMed ID: 22399191
[TBL] [Abstract][Full Text] [Related]
29. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
[TBL] [Abstract][Full Text] [Related]
30. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas.
Terzi NK; Yilmaz I; Oz AB
Turk Patoloji Derg; 2022; 38(2):90-98. PubMed ID: 34558656
[TBL] [Abstract][Full Text] [Related]
31. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
32. [Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification].
Figarella-Branger D; Chappe C; Padovani L; Mercurio S; Colin C; Forest F; Bouvier C
Bull Cancer; 2013; 100(7-8):715-26. PubMed ID: 23831947
[TBL] [Abstract][Full Text] [Related]
33. [Genetics and brain gliomas].
Alentorn A; Labussière M; Sanson M; Delattre JY; Hoang-Xuan K; Idbaih A
Presse Med; 2013 May; 42(5):806-13. PubMed ID: 22789312
[TBL] [Abstract][Full Text] [Related]
34. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas.
Kumar A; Pathak P; Purkait S; Faruq M; Jha P; Mallick S; Suri V; Sharma MC; Suri A; Sarkar C
Cancer Genet; 2015 Mar; 208(3):91-5. PubMed ID: 25794445
[TBL] [Abstract][Full Text] [Related]
36. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
[TBL] [Abstract][Full Text] [Related]
37. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.
Wiencke JK; Zheng S; Jelluma N; Tihan T; Vandenberg S; Tamgüney T; Baumber R; Parsons R; Lamborn KR; Berger MS; Wrensch MR; Haas-Kogan DA; Stokoe D
Neuro Oncol; 2007 Jul; 9(3):271-9. PubMed ID: 17504928
[TBL] [Abstract][Full Text] [Related]
38. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Taylor JW; Chi AS; Cahill DP
Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
[TBL] [Abstract][Full Text] [Related]
39. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
Marko NF; Prayson RA; Barnett GH; Weil RJ
Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
[TBL] [Abstract][Full Text] [Related]
40. Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss.
Kim YH; Nonoguchi N; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Mariani L; Giangaspero F; Tanaka Y; Nakazato Y; Vital A; Mittelbronn M; Perry A; Ohgaki H
Brain Pathol; 2012 Nov; 22(6):834-40. PubMed ID: 22568401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]